Albert Sabin and the Development of the Oral Polio Vaccine

Dr. Albert Sabin remains one of the most significant figures in 20th-century medicine for his development of the oral polio vaccine (OPV), which became a primary tool in the global effort to eradicate poliomyelitis. Unlike the earlier injectable vaccine created by Jonas Salk, Sabin’s version used a live, attenuated virus, providing longer-lasting immunity and interrupting the transmission of the virus within communities, according to the Centers for Disease Control and Prevention (CDC).

How did Albert Sabin’s vaccine differ from the Salk vaccine?

The fundamental difference between the two vaccines lies in the type of virus used. Jonas Salk developed the inactivated poliovirus vaccine (IPV), which uses “killed” virus to trigger an immune response without the risk of causing disease. In contrast, Albert Sabin utilized a live, weakened—or attenuated—form of the virus.

According to the College of Physicians of Philadelphia, Sabin’s oral vaccine offered two distinct advantages: it was easier to administer as a liquid dose on a sugar cube, and it induced mucosal immunity in the gut. This local immunity prevented the virus from replicating in the digestive tract, effectively stopping the vaccinated person from shedding the virus and spreading it to others. This characteristic made the OPV a more effective tool for mass immunization campaigns in environments where the virus was actively circulating.

The path to clinical trials and global impact

Sabin began his work on the vaccine in the late 1940s at the University of Cincinnati. By the mid-1950s, he had identified three strains of the poliovirus and developed attenuated versions that were safe enough for human testing. Because polio was largely under control in the United States by 1955 due to the widespread use of Salk’s IPV, Sabin sought to test his vaccine in populations where the disease was still rampant.

The Encyclopedia Britannica notes that Sabin conducted extensive trials in the Soviet Union and other Eastern European countries between 1957 and 1959. These trials involved millions of children and provided the clinical evidence necessary to prove the vaccine’s safety and efficacy. The U.S. Surgeon General licensed the Sabin vaccine for use in the United States in 1961 and 1962, eventually replacing the Salk vaccine as the standard for routine childhood immunizations for decades.

Why is Albert Sabin’s legacy still relevant today?

Sabin’s commitment to public health extended beyond his laboratory research. He famously refused to patent his vaccine, believing it should be a gift to the world to save children from paralysis and death. This decision helped facilitate the rapid, low-cost production of the vaccine that eventually led to the near-total eradication of wild poliovirus globally.

Today, the medical community maintains a nuanced approach to polio vaccination. While the OPV was critical for global eradication, it carries a rare risk of “vaccine-derived poliovirus” (VDPV), where the live virus in the vaccine can mutate and regain virulence. As a result, the World Health Organization (WHO) reports that many countries, including the United States, have shifted back to the exclusive use of the inactivated (Salk-style) vaccine to eliminate the risk of VDPV while maintaining high levels of population immunity.

Key Facts About Polio Vaccination

• Salk Vaccine (IPV): Introduced in 1955; utilizes inactivated (killed) virus; administered via injection.
• Sabin Vaccine (OPV): Licensed in the U.S. in 1961; utilizes live-attenuated virus; administered orally.
• Public Health Impact: The use of these vaccines has reduced polio cases by more than 99% since 1988, according to the WHO.
• Current Protocol: Most developed nations currently use the IPV to ensure safety while preventing the rare transmission of vaccine-derived viruses.

The history of the polio vaccine serves as a precedent for modern infectious disease control, demonstrating how competing technological approaches—in this case, inactivated versus live-attenuated vaccines—can both play essential, distinct roles in protecting global health.